Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 31, 2023

Details for Patent: 8,410,102

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,410,102 protect, and when does it expire?

Patent 8,410,102 protects MIRVASO and is included in one NDA.

This patent has eighty-seven patent family members in twenty-five countries.

Summary for Patent: 8,410,102
Title:Methods and compositions for treating or preventing erythema
Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one .alpha.-adrenergic receptor agonist and a pharmaceutically acceptable carrier.
Inventor(s): Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), Dejovin; Jack A. (New Brunswick, NJ), Dejovin; Isabelle Jean (New Brunswick, NJ), Liu; Yin-Sang (Princeton Junction, NJ), Leoni; Matthew James (Hampton, NJ)
Assignee: Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:13/072,104
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,410,102
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,410,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 AB RX Yes Yes See Plans and Pricing See Plans and Pricing TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,410,102

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 530185 See Plans and Pricing
Australia 2004242967 See Plans and Pricing
Australia 2005247467 See Plans and Pricing
Australia 2011231543 See Plans and Pricing
Brazil 112012024289 See Plans and Pricing
Brazil PI0511519 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.